FDA approves Sanofi's Cablivi for rare clotting disease

Sanofi (Euronext:SAN; NASDAQ:SNY) said FDA approved Cablivi caplacizumab-yhdp to treat acquired thrombotic

Read the full 123 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE